. Musculoskeletal conditions, including OA, are a major cause of disability worldwide 4 and have a substan tial contribution to healthcare costs, accounting for an estimated 1.0-2.5% of the gross domestic product in the USA, Canada, the UK, France and Australia 5 . Advanced OA often requires joint replacement to reduce pain and disability, and the number of knee replacement surgeries has substantially increased over the past 20 years 6 . The ageing of our population will compound the number of older adults disabled by OA and in need of joint replacement. Improved understanding of how ageing contributes to the development of OA could lead to new therapies that slow or stop the progression of the disease, which would have a major impact on public health.
OA that occurs in young adults is most often caused by a prior joint injury, a process known as post traumatic OA 1 , whereas in older adults a number of factors related to ageing can contribute to the develop ment of OA
. These 'ageing factors' probably work in concert with other OA risk factors. Important differences between joint ageing and OA demonstrate that they are distinct processes (BOX 2) . Although OA is a condition that affects the entire joint 7 and results in joint failure, the majority of research to date has focused on ageingassociated changes in the articular cartilage. However, studies on the meniscus 8 , anterior cruciate ligament 9 and bone 10 have shown agerelated changes similar to those observed in articular cartilage -includ ing loss of cellularity, and disruption and degeneration of the extracellular matrix -suggesting that common processes could be involved.
In 2013, nine cellular and molecular hallmarks of ageing were proposed 11 to highlight the underlying causes of agerelated dysfunction and assist with research into potential therapeutic interventions. These hallmarks include genomic instability, telomere attrition, epigenetic
Stem cell exhaustion
The inability of stem cells to provide a sufficient number of differentiated cells to maintain normal tissue function. Premature stem cell exhaustion can occur under conditions of high demand for progenitors or when aberrant signalling interrupts the maintenance of quiescence.
Senescence-associated secretory phenotype (SASP) . A cellular phenotype that is characterized by the production of high levels of certain inflammatory cytokines and matrix metalloproteinases. The SASP represents a mechanism by which senescent cells may function in a non-autonomous fashion.
alterations, loss of proteostasis, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communica tion. This Review covers selected aspects of ageing that are relevant to OA and, where possible, relates these studies to the hallmarks of ageing.
Ageing, inflammation and OA Mounting evidence suggests that OA is associated with lowgrade systemic and local inflammation 12, 13 . Ageing has likewise been associated with chronic lowgrade inflammation, sometimes referred to as 'inflammaging' (REF. 14) , which could promote OA, although studies to date have not identified the precise mechanisms. Several of the hallmarks of ageing could also have a role in OA, including epigenetic alterations, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence and altered intercellular communication. As discussed further below, increased production of proinflamma tory mediators is a feature of the senescence-associated secretory phenotype (SASP) and could be an important mechanism in OA.
A key cytokine associated with ageing and agerelated disease is IL6. Levels of IL6 in the systemic circulation increase with age 15, 16 and are strongly associated with the risk of OA progression 17, 18 . IL6 is important in the pathogenesis of rheumatoid arthritis, and IL6 inhibition is an effective therapy approved for clinical use in this setting 19 . However, a causal role for IL6 in agerelated OA has not been established, as mice with deletion of the Il6 gene have more severe (rather than less severe) agerelated OA 20 , suggesting that other mediators could be involved. In addition, the levels of multiple proinflam matory and antiinflammatory mediators change with age 16 , and so it is unlikely that the association between age and OA is driven by a single factor.
Inflammaging is probably attributable, at least in part, to the agerelated increase in visceral fat mass that is asso ciated with a decline in muscle mass 21 . Obesity is a well accepted risk factor for OA in all agegroups 3 . Reviews published elsewhere 22, 23 have detailed the potential mechanisms by which obesity leads to OA, and so here we will only summarize the key findings most relevant to agerelated OA. The increase in fat mass with ageing is associated with increased numbers of adipocytes and proinflammatory macrophages in adipose tissue, and these cells produce a number of cytokines and adi pokines that could contribute to OA 24, 25 , although the importance of these mediators in OA remains unclear. Obesity and increased fat mass can also contribute to OA through metabolic alterations that are sometimes referred to as 'metainflammation' (REFS 22, 23) . In addi tion to increased levels of cytokines and adipokines, metainflammation is associated with increased levels of circulating free fatty acids, hyperglycaemia and oxi dative stress, which can all negatively influence joint tissues to promote matrix destruction 22, 23 . Furthermore, obesity associated with low muscle mass (that is, sarco penic obesity) has been associated with knee OA 26 and could contribute to joint instability and an increased risk of falls in older adults, particularly in women 27 . In addition to an agerelated increase in visceral fat, local fat depots such as the infrapatellar fat pad increase with age 28 . Given that this fat pad is proximal to the knee joint and produces the adipokines adiponectin and lep tin, as well as basic fibroblast growth factor (bFGF; also known as FGF2), vascular endothelial growth factor, TNF and IL6 (REF. 29 ), it is plausible that an agerelated increase in fat pad volume could contribute to OA. However, in vitro studies of conditioned media from infrapatellar fat pads removed from patients with end stage knee OA found a protective rather than catabolic effect on bovine cartilage explants 30 . Cellular senescence and the SASP Cellular senescence is one of the hallmarks of ageing, and chondrocytes have many features that are character istic of senescent cells during ageing and during OA 31, 32 ( FIG. 1) . The observation that OA catalyses the develop ment of senescence indicates that cellular stresses prob ably have a key role in establishing this phenotypic state. A key challenge has been deciding how to best define chondrocyte senescence and determine the underlying mechanisms that might be targeted therapeutically. Morphological changes and permanent replicative arrest after monolayer expansion have defined cellular senes cence for in vitro settings, but defining cellular senescence in vivo has proved more difficult 33 . Two distinguishing characteristics of senescent cells are stressinduced permanent proliferative arrest and resistance to both mitogenic and oncogenic stimuli 33 , both of which are challenging to assess in chondro cytes. Chondrocytes exhibit low proliferation rates, which hinders the measurement and interpretation of the functional impact of a further reduction in prolif eration 34 . Lineagetracing experiments in mice indicate that the proliferation of particular chondrocyte sub populations could help to maintain cartilage tissue 35 , suggesting, therefore, that the loss of proliferation in these cells due to senescence could contribute to OA progression. The other defining feature of senescence
Key points
• Ageing-associated changes promote the development of osteoarthritis (OA), but ageing and OA are independent processes • Several hallmarks of ageing could contribute to OA: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication • The increase in fat mass and related metabolic changes that occur with ageing can result in ageing-related inflammation (referred to as 'inflammaging'), a chronic low-grade systemic proinflammatory state • Elevated levels of reactive oxygen species can contribute to OA by causing oxidative damage and disrupting normal cell signalling, leading to imbalanced anabolic and catabolic activity and ultimately cell death • Chondrocytes can undergo cellular senescence with age and OA in response to growth signals released as a result of underlying cellular damage • The non-enzymatic crosslinking of collagen that occurs with ageing alters the mechanical properties of cartilage, and the resulting changes to mechanotransduction pathways reduce extracellular matrix synthesis by chondrocytes is a beneficial function of preventing the division of transformed cells 36 . Chondrosarcomas typically derive from the growth plate and perichondrium but not from articular cartilage 37 , suggesting that articular cartilage might be inherently unlikely to undergo uncontrolled growth. This characteristic presents a challenge for the identification of senescent chondrocytes on the basis of an increased resistance to oncogenic transformation.
Cellular senescence could have other functional roles aside from inhibition of proliferation, as the SASP is defined by the production of high levels of proinflamma tory cytokines and matrixdegrading enzymes 38 . Indeed, the SASP seems to be regulated independently from cell cycle arrest 39, 40 . Some of the most highly upregulated SASPrelated factors, such as IL1α, IL6 and monocyte chemoattractant protein 1 (MCP1; also known as CC chemokine ligand 2 (CCL2)) are found in OA cartilage 41 , hindering efforts to determine whether the level of a particular mediator is due to senescence or a result of OA. The cell type responsible for producing these cytokines is also difficult to determine. As these factors are also found in the synovial fluid, they could be produced by cells other than chondrocytes, such as cells in the meniscus, synovium or bone 7 . Future work is needed to determine whether any of these cell types display other features of senescence.
The induction of chondrocyte senescence
A detailed understanding of how chondrocytes enter the senescent state might enable the development of therapies designed to prevent such a phenotypic switch during OA. One model proposes that senescence occurs during conditions characterized by simultaneous signals for cell cycle arrest and cell growth 7, 42 , and aged cartilage tissue has the potential to provide both these cues.
The cumulative DNA damage and oxidative stress that occurs with ageing and in the OA tissue micro environment alters gene expression patterns in chon drocytes 7, 43 and could cause telomere attrition due to targeted DNA damage 41, 44 . Notably, stem cells and post mitotic cells such as neurons and chondrocytes can be particularly susceptible to the accumulation of cellular damage during the long interval between replicative events 45, 46 . One common consequence of accumulating DNA damage is the upregulation of cell cycle inhibitors, such as p16 INK4A and p21, which mediate the stable arrest that is associated with senescence 33 . Chondrocytes from patients with OA have increased p16
INK4A expression compared with those from agematched controls, pos sibly due to a reduction in expression of the microRNA miR24 (REF. 47 ). Indeed, knocking down miR24 led to increased expression of p16 INK4A in an in vitro pellet cul ture model 47 . These observations in chondrocytes seem to be aligned with a model explored in mouse muscle stem cells, in which increased p16
INK4A expression with age made cells more likely to undergo senescence during subsequent proliferation after injury 48 . The second signal required for establishing senescence, a strong growth signal, can be provided in the form of growth factors that are either directly released from dam aged cartilage or synthesized at high levels by chondrocytes during OA. For example, bFGF is released from damaged cartilage tissue 49 and can be detected in focal clusters of chondrocyte proliferation that develop near areas of cartilage damage 50 . As a downstream result of signalling by inflammatory cytokines associated with OA, expression of bone morphogenetic protein 2 (BMP2) is increased 51 , thereby stimulating enhanced turnover of extracellular matrix 52 . Although their competence for proliferation indicates that these chondrocytes are not senescent, cells that enter the cell cycle in the context of potentially dam aging stimuli have an increased likelihood of entering senescence as opposed to returning to quiescence 53, 54 . Observations that senescence occurs after monolayer expansion of chondrocytes (reviewed elsewhere 55 ) provide further evidence that contexts of increased proliferation correlate with emergence of the senescent phenotype.
The role of circadian signals
Also of potential interest is the finding that chondrocytes have an intrinsic circadian clock which is disrupted in cartilage from aged mice 56 . A decline in expression of the circadian clock gene BMAL1 (also known as ARNTL) has Box 1 | Age-related factors that contribute to osteoarthritis development
• Reduced muscle mass and increased fat mass alter joint loading and are associated with an increase in adipokine and cytokine production, resulting in low-grade systemic inflammation 109 .
• Changes in the extracellular matrix -including the accumulation of advanced glycation end-products, reduced aggrecan size, reduced hydration and increased collagen cleavage -alter the mechanical properties of cartilage and make it more susceptible to degeneration 31 .
• Extracellular matrix disruption and reduced cell density in the meniscus and ligaments promote degeneration and can potentially alter joint mechanics 8, 9 .
• The function of subchondral bone is impaired due to reduced numbers of osteocytes and altered mineral composition 10 .
• Mitochondrial dysfunction, oxidative stress and reduced autophagy in chondrocytes alters their function, promoting catabolic processes and cell death over anabolic processes 31 .
Box 2 | Differences between normal joint ageing and osteoarthritis
• With normal joint ageing, articular cartilage remains intact but loses thickness and has a reduced glycosaminoglycan (GAG) content. With osteoarthritis (OA), fibrillation of the cartilage surface occurs in focal areas and can be associated with a complete loss of staining for GAGs 31, 110 .
• Non-enzymatic crosslinking of collagen by advanced glycation end-products (AGEs) increases in cartilage with age 101 . A mouse model of injury-induced OA demonstrated that collagen crosslinking occurs through a distinct mechanism involving lysyl oxidase 104 .
• The density of chondrocytes in cartilage decreases with age, but chondrocyte 'clusters' emerge during the development of OA near sites of tissue damage and may indicate attempted repair or altered cellular signals 31, 110 .
• Aged chondrocytes have reduced levels of extracellular matrix gene expression and synthesis, whereas during OA chondrocytes become highly active with increases in both anabolic processes (for example, matrix synthesis) and catabolic pathways (for example, those induced by inflammatory cytokines) 31, 110 .
• Synovial inflammation and hypertrophy occur in OA but have not been described in normal joint ageing 7 .
• Bone mass and density decrease with ageing, whereas subchondral bone thickening is seen in patients with OA 7 . 57 and has been noted to occur in human OA chon drocytes and in the cartilage of aged mice 58 . Mice with cartilagespecific deletion of Bmal1 developed premature knee cartilage lesions that appeared at 2 months of age and became progressively more severe in adult animals 58 . However, no other OAassociated changes in the bone, ligaments or synovium were evident in these mice, and the finding that the cartilage changes were detectable before the mice were skeletally mature suggests that the phenotype is the result of a developmental defect rather than OA. Further work is needed to determine the role of BMAL1 and the circadian clock in agerelated human OA.
Therapeutic targeting of senescence
One emerging therapeutic strategy for agerelated dis eases is to specifically kill senescent cells in order to prevent the detrimental secretion of SASPrelated fac tors. Although this approach has not yet been explored in OA, the concept builds on studies that eliminated p16 INK4A positive cells in mouse models of premature 59 and natural ageing 60 . Drugs that eliminate senescent cells in aged tissue would ideally mimic the efficient clearance of senescent cells that occurs after wound repair 61 . The 'senolytic' compounds dasatanib and quercetin target senescent cells by inhibiting the antiapoptotic pathways that are upregulated in senescent cells 62 . One antiageing effect of this treatment was protection from proteogly can loss in the intervertebral disc of Ercc1mutant mice 62 (a model of accelerated ageing based on compromised DNA damage repair). Although articular cartilage was not investigated in this study, other work has shown that ERCC1mediated DNA repair helped to restrain senescence in human articular chondrocytes 63 . A sepa rate study further supports the strategy of inhibiting antiapoptotic pathways by identifying navitoclax as an inhibitor of Bcell lymphoma family proteins that spe cifically targets senescent human fibroblasts in vitro and mouse stem cells in vivo 64 .
Another therapeutic approach could be to interfere with inflammatory pathways that are active in senes cent chondrocytes. Rapamycin inhibits the translation of SASP proteins in human fibroblasts through decreas ing the rate of IL1α translation, which is regulated by serine/threonineprotein kinase mTOR (also known as mammalian target of rapamycin) 65 . With increased progress in the understanding of how senescence is reg ulated in chondrocytes, particular cellular features could provide other novel drug targets for OA.
Oxidative stress and the mitochondria Mitochondrial dysfunction is a hallmark of ageing that has attracted particular attention in the context of OA. The free radical theory proposes that cellular damage occurring as a result of excessive levels of reactive oxygen species (ROS) substantially contributes to the develop ment of the ageing phenotype and to the progression of agerelated diseases 66 . However, in addition to cellular damage, elevated levels of ROS produced as a result of ageassociated oxidative stress also promote disease by disturbing homeostatic physiological cell signalling [66] [67] [68] . Mitochondrial function has long been recognized to decline during ageing, and a causative link between mitochondrial dysfunction, oxidative stress and the age ing phenotype has been proposed 66, 69 . Evidence from a 2015 study 70 demonstrates that, compared with normal chondrocytes, chondrocytes from patients with OA have reduced mitochondrial mass and mitochondrial DNA content along with reduced levels of electron transport chain proteins and proteins involved in mito chondrial biogenesis. The researchers confirmed that some of these changes occurred during ageing and were independent of OA by analysing mouse cartilage tissue sections. Interestingly, protein levels of nuclear receptor erythroid 2related factors 1 and 2 (also known as NRF1 and NRF2, respectively), which confer cellular protection through regulation of antioxidant gene expression, were also decreased in chondrocytes from patients with OA compared with those from healthy controls 70 . As mitochondria are an important source of ROS, agerelated mitochondrial dysfunction that leads to an imbalance between the production of ROS and the antioxidant capacity of the cell has been identified as a contributing factor in the development of OA 68, 71, 72 ( FIG. 2) . Mice with posttraumatic OA showed elevated intracellular and mitochondrial superoxide generation, which was associated with downregulation of mito chondrial superoxide dismutase 2 (SOD2) expression 73 . Furthermore, in this same model, SOD2 loss resulted in greatly increased agerelated cartilage degeneration 73 .
In vitro studies using paraquat to induce mitochondrial superoxide generation in primary mouse articular chon drocytes led to substantial mitochondrial dysfunction, 
↑ Chondrocyte catabolism
Mitochondrion along with reduced expression of both antioxidant genes (including Sod2) and anabolic genes in cartilage, whereas catabolic gene expression was upregulated 73 . These data are in accordance with other studies demonstrating downregulation of SOD2 expression at the mRNA and protein levels in cartilage from both humans [74] [75] [76] and animals 76 with OA, and support the hypothesis that mitochondrial dysfunction and the associated redox imbalance is a key mechanism contributing to cartilage degeneration and the pathogenesis of OA.
Consistent with the concept that agerelated oxidative stress alters cell signalling, studies have demonstrated an agerelated disruption ofinsulinlike growth factor 1 (IGF1) signalling in human chondrocytes that results in reduced extracellular matrix gene expression and protein synthesis 77, 78 . In human chondrocytes from older adults, this effect was associated with an increased sen sitivity to oxidative stress, which resulted in inhibition of IGF1mediated activation of RACα serine/threonine protein kinase (AKT) and increased activation of cata bolic mitogen activated protein kinase (MAPK) signalling pathways 78 . A key mechanism by which ROS regulate cell signal ling is through oxidative posttranslational modifications of specific thiol groups in proteins that contain reactive cysteines 79 . Cysteine oxidation initially results in the for mation of a cysteine sulfenic acid (CysSOH) in a process known as Ssulfenylation. In a 2016 study, chondrocytes from patients with OA had an increased basal level of Ssulfenylation compared with those from healthy con trols 80 . ROS induced sulfenylation of multiple chondro cyte proteins including the tyrosine kinase SRC, the activity of which promoted an increase in the production of matrix metalloproteinase 13 (MMP13) 80 . These data suggest that ROSinduced sulfenylation of chondrocyte proteins can alter signalling pathways that can promote cartilage degradation.
In the presence of excessive levels of ROS, cysteine oxidation can proceed from cysteine sulfenic acid to sulfinic (CysSO 2 H) or sulfonic (CysSO 3 H) acid; this socalled hyperoxidation can lead to the inactivation of redoxsensitive proteins. Hyperoxidation of the peroxi redoxin family of antioxidant enzymes has been dem onstrated in cartilage samples from older adult humans and patients with OA 81 . Conditions of oxidative stress (induced in vitro with the ROS generator menadione) led to an agerelated increase in peroxiredoxin hyper oxidation, which was associated with both inhibition of prosurvival cell signalling and p38 MAPKinduced chon drocyte cell death 81 . Importantly, reduction of ROS levels by mitochondrionspecific overexpression of the antioxi dant enzyme catalase prevented peroxiredoxin hyperoxi dation in vitro and reduced the severity of agerelated OA in mice in vivo 81 . Collectively, these studies highlight ROS as crucial secondary signalling molecules in chondrocytes that warrant further study in the context of ageing and OA.
Dysfunctional energy metabolism
Another hallmark of ageing is dysregulated nutrient sensing. 5ʹAMP activated protein kinase (AMPK) is a key regulator of cellular metabolism and energy balance that is activated by stressors that enhance the cellular AMP:ATP ratio 82 . The activity of AMPK and its regulatory upstream kinase, serine/threonineprotein kinase STK11 (also known as liver kinase B1 (LKB1)), is reduced in cartilage from aged mice and mice with OA, as well as in bovine chondrocytes after dynamic compressioninduced bio mechanical injury 83 . Similarly, OAassociated reductions in AMPK activity have been observed in human chondrocytes and cartilage 84 , and this reduced activity has been associated with substantially reduced mitochondrial biogenesis 70 . Figure 2 | Mitochondrial dysfunction, oxidative stress and changes in normal cell signalling in ageing and osteoarthritis. Mitochondrial dysfunction in both ageing and osteoarthritis (OA) is characterized by reduced mitochondrial integrity (mass, number and DNA content) and impaired electron transport chain (ETC) function. These features contribute to increased production of reactive oxygen species (ROS). Concomitant reductions in mitochondrial antioxidant capacity -including reduced mitochondrial superoxide dismutase 2 (SOD2) levels and peroxiredoxin hyperoxidation -lead to enhanced oxidative stress and ROS-mediated damage in the mitochondria (indicated by red lightning bolts). In ageing and OA, extra-mitochondrial antioxidant systems (namely, SOD1, catalase and glutathione synthetase; not shown) are also considerably less active, which exacerbates oxidative stress. ROS cause damage to proteins, lipids and DNA, increase chondrocyte catabolism and, importantly, lead to disturbances in normal cell signalling. These disturbances can include inhibition of pro-survival insulin-like growth factor 1 (IGF1) signalling and increased catabolic mitogen-activated protein kinase (MAPK) signalling. Increased levels of ROS can also result in increased protein thiol oxidation, resulting in S-sulfenylation or, when excessive, hyperoxidation of reactive protein cysteines, which might contribute to altered cell signalling. mtDNA, mitochondrial DNA; ERK, extracellular signal-regulated kinase; IGFR, IGF receptor; IRS1, insulin receptor substrate 1.
Advanced glycation end-products (AGEs). A diverse set of molecules formed by non-enzymatic reaction of proteins with reducing sugars such as glucose and ribose.
Anabolic dynamic compression
A process by which physical compression of cells within a tissue promotes an anabolic response by the cells.
Importantly, AMPK might also modulate key homeo static signalling pathways through regulation of autophagy, a cellular process that removes damaged and dysfunctional organelles and proteins 82, 85 . Autophagy is relevant to another hallmark of ageing: loss of proteostasis. Transgenic overexpression of AMPK delays the onset of the ageing phenotype through direct upregulation of autophagy in Drosophila melanogaster, which ultimately increases the lifespan of these organisms 86 . Consistent with this obser vation, the expression of key autophagy proteins is consid erably reduced in cartilage from aged mice compared with that from young mice, and these changes are associated with increased levels of apoptosis and cartilage degener ation 87 . Similar results have also been found in a mouse model of posttraumatic OA 88 , implicating dysfunctional autophagy as a key mechanism in both ageing and OA. Although AMPK levels were not measured in these posttraumatic OA studies, other work has demonstrated that AMPK signalling stimulates autophagy in chon drocytes 89 . As inhibition of mTOR signalling is a widely investigated strategy to prevent agerelated disease 90 , the fact that cartilagespecific loss of mTOR increased AMPK levels and autophagy, and was sufficient to protect mice from OA following surgery, is of particular interest 91 . Taken together, a plausible interpretation of these findings is that agerelated and OArelated reductions in AMPK signalling reduce autophagy and contribute to the cellular dysfunction observed in OA cartilage, a connection that is worthy of future investigation.
In addition to AMPK, many lines of evidence suggest that the evolutionarily conserved sirtuin (SIRT) family of NAD + dependent deacetylase proteins also contrib utes to cellular homeostasis through regulation of energy balance. This regulation is achieved via direct nutrient sensing, which can contribute to increased lifespan in model organisms, such as worms and flies 92 . However, whether overexpression of sirtuins can have a direct longevitypromoting effect remains unclear 93 . SIRT6 has been identified as a crucial regulator of processes that are hypothesized to be directly involved in ageing, including metabolic homeostasis, genome stability and transcrip tion 94 . Sirt6knockout mice have reduced IGF1 levels and accelerated ageinglike degenerative processes that ultimately lead to premature death, which suggests a role for SIRT6 in ageing 95 . Similarly, male transgenic mice overexpressing Sirt6 had an increased lifespan, in part due to regulation of IGF1 signalling 96 , which suggests that agerelated loss of SIRT6 activity could contribute to ageing by disturbing normal cell signalling pathways.
In cartilage, research has predominantly focused on the role of SIRT1 (reviewed elsewhere 97 ). As such, there is a paucity of research on how other sirtuins regulate chondrocyte function. However, depletion of SIRT6 in human chondrocytes (achieved using RNA interference) resulted in substantially increased DNA damage and telomere dysfunction, which was associated with pre mature senescence 98 . SIRT6 depletion also increased expression of MMP1 and MMP13, which are implicated in the pathogenesis of OA. Compared with cells from normal human tissue, human OA chondrocytes show reduced expression of SIRT6 at both the mRNA and protein level, and lentivirusinduced overexpression of SIRT6 in the knee joint protects young mice from surgi cally induced OA 99 . These studies highlight a potential role for SIRT6 in cartilage homeostasis that warrants further investigation.
Changes in the extracellular matrix Articular cartilage is a loadbearing tissue, and the ability of chondrocytes to sense and respond to mechanical signals is essential for maintaining joint homeostasis (reviewed elsewhere 100 ). Accumulation of advanced glycation end-products (AGEs) with ageing causes non enzymatic collagen crosslinking that directly alters the mechanical properties of the extracellular matrix 101 . However, a canine model using ribose and threose injec tions to increase AGE levels in young animals to match those of aged controls was insufficient to initiate OA 102 . Nevertheless, chondrocytes did synthesize fewer proteo glycans in the highly crosslinked tissue, which might indicate that compromised cellular function would prevent sufficient tissue maintenance in the context of ageing or injury. This possibility is supported by a study in rabbits, in which forced exercise in combination with ribose injections did induce OA, through AGEmediated suppression of protective chondrocyte signalling 103 .
Whether limiting AGE accumulation would be suf ficient to prevent agerelated OA remains unclear, but genetic deletion of lysyl oxidase (an enzymatic collagen crosslinker that is upregulated by joint injury) protected mice from injuryinduced OA 104 . The potential relevance of this finding to AGEs and thus ageing was suggested by the finding that collagen crosslinking induced by AGEs and by lysyl oxidase had similar effects on chondrocyte signalling in collagen gels and on the development of OA after injury.
Chondrocytes integrate signals from mechanotrans duction pathways that sense changes in the extracellular matrix and those initiated by soluble factors, and both types of signal are affected by ageing. Mechanical com pression of bovine cartilage stimulates increased expres sion of the gene encoding transforming growth factorβ (TGFβ) and the subsequent phosphorylation of SMAD2 and SMAD3 through TGFβ receptor type 1 (TGFR1), which increases matrix synthesis and limits catabolic signalling 105 . However, ageing causes a significant loss in expression of TGFR1, resulting in a shift that favours TGFβ signalling through serine/threonineprotein kinase receptor R3 (SKR3; also known as TGFβ super family receptor type I). SKR3mediated signalling leads to phosphorylation of SMAD1, SMAD5 and SMAD8, which is associated with an increase in catabolic signal ling and increased production of MMP13 (REF. 106 ). In a 2016 study of bovine cartilage explants subjected to anabolic dynamic compression, tissues from aged animals had deficient phosphorylation of SMAD2 and SMAD3 in response to loading compared with explants from young animals 105 . The exact mechanism responsible for this effect is difficult to deduce because, compared with young explants subjected to the same load, aged tissue showed less deformation, exhibited less upregulation of growth factors and also had lower levels of TGFR1 on the cell surface. However, previous work using a hydrogel system with varied stiffness revealed that mouse chondro cytes show a maximal response to exogenous TGFβ at a physiologically relevant stiffness of 500 kPa 107 , indicating that the agerelated increase in matrix stiffness probably contributes to the reduced phosphorylation of SMAD2 and SMAD3 in aged tissue.
Conclusions
Researchers are becoming increasingly interested in elucidating the mechanisms by which ageing promotes the development and progression of OA. Studies in the early 2000s detailed agerelated changes in the extracell ular matrix, such as the accumulation of AGEs, which could promote OA by altering the mechanical proper ties of joint tissues. Subsequent research has focused on agerelated cellular changes that include not only an accumulation of damaged proteins, lipids and DNA, but also alterations in mitochondrial function, levels of ROS and energy metabolism that disrupt cell signalling and function. These changes promote catabolic activity over anabolic activity and eventually result in cell death. We can easily envision how these changes could result in joint tissue degeneration and matrix loss, but the precise mechanisms need to be clarified. The concept of hall marks of ageing suggests that common mechanisms will drive dysfunction in various tissues and organ systems that are most affected by ageing. These hallmarks repre sent areas for further research into elucidating the con nections between ageing and OA. Although the majority of research into the effects of ageing continues to focus on articular chondrocytes, further studies are needed to determine whether similar mechanisms are at play in other cells of the joint that are affected by OA, in order to find common targets for intervention.
A primary goal of ageing research is to better under stand common mechanisms that could be targeted with the intent of delaying loss of function in more than a single system, which would result in improved 'healthspan' rather than simply extending lifespan. Heterochronic parabiosis experiments, in which the circulatory systems of young and old animals are joined, have revealed sys temic factors that alter the ageing phenotype, including growth and differentiation factor 11 (GDF11), oxytocin and IL15, which might be able to reduce ageing in mul tiple organ systems 108 . An important aim of future studies will be to determine whether these ageingassociated factors influence the development of OA.
Another emerging approach is the development of senolytic agents that would target and remove senescent cells 62, 64 . These and other therapies that target ageing processes could be developed into novel treatments for OA
. Given the prevalence of conditions such as OA in older adults and the importance of the musculoskeletal system in physical function, achieving improvements in healthspan will certainly require interventions that benefit the musculoskeletal system.
Box 3 | Therapeutic targeting of ageing-related processes in osteoarthritis
• Interventions designed to extend 'healthspan' by targeting systemic ageingrelated processes could potentially delay or prevent various chronic diseases, including osteoarthritis 111, 112 .
• Senolytics, such as dasatanib and quercetin, are being designed to specifically kill senescent cells; removal of these cells might alleviate their harmful effects on neighbouring cells, including the release of proinflammatory factors that characterize the senescence-associated secretory phenotype (SASP) 62 .
• Agents that activate 5ʹ-AMP-activated protein kinase (AMPK), such as metformin, could restore physiological levels of autophagy and promote proteostasis 112 .
• Sirtuin activators could restore normal nutrient sensing and energy metabolism 112 .
• Antioxidants targeted to the mitochondria or designed to restore homeostatic redox signalling could counteract mitochondrial dysfunction and altered intracellular signalling 113 .
